Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Galectin Therapeutics (NASDAQ: GALT) announced the acceptance of three abstracts from its ongoing Phase 2b/3 NAVIGATE trial for presentation at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting. The trial focuses on patients with MASH cirrhosis and portal hypertension. The posters will be presented on November 18, 2024, during the 'Portal Hypertension and Other Complications of Cirrhosis' session.
The accepted abstracts cover:
- Evaluation of esophageal and gastric varices in cirrhotic patients
- Baseline patient characteristics from the NAVIGATE trial
- Identification of esophageal varices in patients with compensated MASH cirrhosis
The abstracts will be available on the AASLD website and in the October supplement of the AASLD journal, Hepatology.
Galectin Therapeutics (NASDAQ: GALT) ha annunciato l'accettazione di tre abstract del suo studio in corso di Fase 2b/3 NAVIGATE per la presentazione all' American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting. Lo studio si concentra su pazienti con cirrosi MASH e ipertensione portale. I poster saranno presentati il 18 novembre 2024, durante la sessione 'Ipertensione portale e altre complicazioni della cirrosi'.
Gli abstract accettati riguardano:
- Valutazione delle varici esofagee e gastriche nei pazienti cirrotici
- Caratteristiche basali dei pazienti dallo studio NAVIGATE
- Identificazione delle varici esofagee nei pazienti con cirrosi MASH compensata
Gli abstract saranno disponibili sul sito web dell'AASLD e nel supplemento di ottobre della rivista AASLD, Hepatology.
Galectin Therapeutics (NASDAQ: GALT) anunció la aceptación de tres resúmenes de su ensayo en curso de Fase 2b/3 NAVIGATE para su presentación en la American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting. El ensayo se centra en pacientes con cirrosis MASH e hipertensión portal. Los pósters se presentarán el 18 de noviembre de 2024, durante la sesión 'Hipertensión portal y otras complicaciones de la cirrosis'.
Los resúmenes aceptados cubren:
- Evaluación de varices esofágicas y gástricas en pacientes cirróticos
- Características basales de los pacientes del ensayo NAVIGATE
- Identificación de varices esofágicas en pacientes con cirrosis MASH compensada
Los resúmenes estarán disponibles en el sitio web de AASLD y en el suplemento de octubre de la revista AASLD, Hepatology.
갈렉틴 테라퓨틱스(NASDAQ: GALT)는 세 개의 초록이 2024년 미국 간 질환 연구 협회(AASLD) 간 회의에서 발표될 수 있도록 수락되었다고 발표했습니다. 이 임상시험은 MASH 간경변 및 문맥 고혈압 환자에 초점을 맞추고 있습니다. 포스터는 2024년 11월 18일에 '문맥 고혈압 및 간경변의 기타 합병증' 세션에서 발표될 것입니다.
수락된 초록은 다음을 포함합니다:
- 간경변 환자에서 식도 및 위 정맥류 평가
- NAVIGATE 시험의 환자 기초 특성
- 보상성 MASH 간경변 환자에서 식도 정맥류 식별
초록은 AASLD 웹사이트 및 10월호 AASLD 저널인 Hepatology에 게재됩니다.
Galectin Therapeutics (NASDAQ: GALT) a annoncé l'acceptation de trois résumés de son essai en cours de Phase 2b/3 NAVIGATE pour présentation lors de la American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting. L'essai se concentre sur des patients atteints de cirrhose MASH et d'hypertension portale. Les affiches seront présentées le 18 novembre 2024, lors de la session 'Hypertension portale et autres complications de la cirrhose'.
Les résumés acceptés portent sur :
- Évaluation des varices œsophagiennes et gastriques chez les patients cirrhotiques
- Caractéristiques de base des patients de l'essai NAVIGATE
- Identification des varices œsophagiennes chez les patients avec cirrhose MASH compensée
Les résumés seront disponibles sur le site Web de l'AASLD et dans le supplément d'octobre de la revue de l'AASLD, Hepatology.
Galectin Therapeutics (NASDAQ: GALT) hat die Annahme von drei Abstracts aus seiner laufenden Phase 2b/3 NAVIGATE-Studie zur Präsentation auf dem American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting bekannt gegeben. Die Studie konzentriert sich auf Patienten mit MASH-Zirrhose und portaler Hypertension. Die Poster werden am 18. November 2024 während der Sitzung 'Portale Hypertension und andere Komplikationen der Zirrhose' präsentiert.
Die angenommenen Abstracts behandeln:
- Bewertung von Speiseröhren- und Magenvarizen bei zirrhotischen Patienten
- Basismerkmale der Patienten aus der NAVIGATE-Studie
- Identifizierung von Speiseröhrenvarizen bei Patienten mit kompensierter MASH-Zirrhose
Die Abstracts werden auf der AASLD-Website und im Oktober-Supplement der AASLD-Zeitschrift Hepatology verfügbar sein.
- Acceptance of three abstracts for presentation at a major liver disease conference
- Ongoing progress in Phase 2b/3 NAVIGATE trial for MASH cirrhosis and portal hypertension
- None.
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and portal hypertension have been accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD)’s annual meeting, 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California.
All three posters highlighting clinical data will be presented at the “Portal Hypertension and Other Complications of Cirrhosis” session taking place 8:00 am – 5:00 pm on November 18, 2024:
Title: Evaluation of esophageal and gastric varices in cirrhotic patients with portal hypertension: a central evaluation system for clinical research.
Abstract Number: 4118
Presenter: Naim Alkhouri, M.D., Arizona Liver Health, Chandler, AZ
Title: Baseline patients’ characteristics from NAVIGATE, a seamless adaptive Phase 2b/3 trial of Belapectin in MASH cirrhosis and portal hypertension.
Abstract Number: 4063
Presenter: Khurram Jamil, M.D., Chief Medical Officer, Galectin Therapeutics
Title: In patients with compensated MASH cirrhosis with platelet count < 150,000/µL and radiologic findings of portal hypertension, a third are identified with esophageal varices on screening Esophago-Gastroduodenoscopy.
Abstract Number: 4125
Presenter: Laura Ladron deGuevar, M.D., CIAID - Centro de Investigacion y Atencion Integral Durango, S.C.
Abstracts are available for viewing by attendees on the AASLD website and will also be featured in the October supplement to the AASLD journal, Hepatology.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Investors Relations Contacts:
Kevin Gardner
kgardner@lifesciadvisors.com
Chris Calabrese
ccalabrese@lifesciadvisors.com
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.
FAQ
What is the significance of Galectin Therapeutics (GALT) having three abstracts accepted for the AASLD 2024 Liver Meeting?
When and where will Galectin Therapeutics (GALT) present their abstracts at the AASLD 2024 Liver Meeting?
What is the focus of Galectin Therapeutics' (GALT) NAVIGATE trial presented in the AASLD 2024 abstracts?
